PDCD1 and cancer: In line with the immunogenic features, cancer immunotherapy has shown profound efficacy to prolong patient survival in clinical trials, eventually leading to approval of pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, for the treatment of TNBC patients (ClinicalTrials.gov Identifier: NCT03036488, last visited on 22 October 2021).